CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
EN
Home / Amgen INC (AMGN) / avacopan
Forward catalyst · AMGN

avacopan

Sponsor Amgen INC · listed as AMGN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

avacopan is a clinical-stage drug asset sponsored by Amgen INC, listed as AMGN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jul 18, 2027 (day precision, medium confidence), tied to trial NCT06321601. The asset is in Phase 3 and currently active not recruiting, studied in Vasculitis. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-07-18
As disclosedJul 18, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06321601
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorAmgen
Listed asAMGN
Condition(s)Vasculitis
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.

Get the full dataset — $499 →   More AMGN catalysts

Related catalysts and sponsor